The most common avoidable error in reconstructive fat grafting is not a technical one. It is trying to finish in one operation.
The reasoning behind the attempt is sound enough: the patient has already had surgery, theatre time is expensive, and every additional anaesthetic is a burden to be justified. The problem is that the recipient bed does not care about any of that. It has a ceiling, the ceiling is lower than the defect, and exceeding it does not merely waste the excess — it damages what would otherwise have survived.
Why one sitting is not enough
The ceiling has two components. The first is geometric: there is only so much space within diffusion distance of living tissue, and once the available surface is populated, additional fat has nowhere to go except into parcels that are too large or into pools between them. The second is mechanical: fat raises interstitial pressure, and pressure closes the capillaries the graft is relying on.
Both components mean the same thing in practice. Past a certain volume, added fat does not add retained volume.
Note what the curve does after the turn. It does not flatten; it falls. That is the part that makes overfilling worse than merely pointless. Beyond the turn, the additional fat competes with the fat already placed, and the outcome can be less retained volume than a more modest graft would have achieved — with fat necrosis, oil cysts and palpable lumps on top.
The clinical trap is that the turn is invisible at the table. The breast looks full at the end of the operation in both cases. The difference appears at three months, and by then the surgeon has attributed the shortfall to the patient’s biology rather than to the volume chosen.
Staging as the default, not the fallback
If the bed has a ceiling and the defect exceeds it, the answer is sessions. This is worth stating positively, because staging is often presented to patients — and sometimes framed internally — as what happens when the first attempt did not work. It is not. It is the plan.
Each session does two things. It delivers the volume that the bed will support, and it changes the bed. Grafted fat that takes brings its own vascularity, increases the thickness and compliance of the tissue, and raises the ceiling for the next session. The capacity of the bed is therefore a function of what has already been done to it, which is why the second session can often accept more than the first — and why the sequence matters more than the arithmetic.
The interval between sessions is a clinical judgement, not a fixed number, and it depends on how long the tissue takes to settle and revascularise in that particular patient. An irradiated field behaves differently from a virgin one; a field that has already received two grafts behaves differently again.
Consent, and the conversation this changes
A staged plan has to be a staged consent. A patient who was told “a fat grafting procedure” and finds themselves booked for a third will reasonably conclude that something went wrong, even if the plan was always three. A patient who was told from the outset that the defect requires more than one bed can absorb at once arrives at the third session with an accurate model of what is happening.
This is also where the distinction between reabsorption and failure needs to be made explicitly. Some reabsorption is expected and normal; it is not a complication and it is not a sign of poor technique. Our patient-facing article on what to expect from rigottomy and fat grafting covers this in language that can be used in clinic, and questions to ask your surgeon is a useful handout for patients trying to understand a multi-stage plan.
Raising the ceiling rather than pushing against it
If the ceiling is set by the bed, the alternative to more sessions is a better bed. Three approaches are in routine use, and they are not mutually exclusive.
Release. Percutaneous release converts a fibrous plate into a compliant lattice, creating both space and surface. This is the mechanism described in rigottomy and in the companion article on release mechanics and macrocavity avoidance.
External expansion. Pre-expansion of the recipient site increases its volume and vascularity before grafting, at the cost of a compliance and adherence burden on the patient.
Graft quality. A graft with more intact adipocytes and an intact stromal vascular fraction makes better use of whatever ceiling exists. This is the processing question covered in processing and graft quality and in ExaFat fat processing.
Measuring, so the next session is planned rather than guessed
A staged plan is only as good as the assessment between stages, and “it looks about right” is not an assessment that survives six months and a change of clinic. Volumetric imaging, standardised photography, or at minimum a consistent and recorded method of estimation makes the difference between a plan and a sequence of improvisations.
The same argument applies to the donor site, which is finite and which has its own contour consequences if repeatedly harvested from the same area.
Where it fits in reconstruction
In implant-based reconstruction, fat grafting is usually a refinement stage rather than the main event: correcting upper-pole hollowing, softening a visible implant edge, thickening a thin flap. The volumes are smaller and the ceiling argument is correspondingly less pressing, but the geometry argument is not — a bolus placed under thin skin to hide an implant edge is exactly the situation in which a large parcel is most tempting and least survivable. See combining matrix and fat grafting in prepectoral reconstruction for how the stages are usually sequenced.
In total autologous reconstruction by fat grafting alone, the ceiling argument is the whole planning problem, and the number of sessions is the honest headline figure the patient needs at the first consultation.
The short version
The bed sets the volume; the volume sets the number of sessions; the number of sessions has to be in the consent. A surgeon who plans around the ceiling gets a predictable result in three operations. A surgeon who pushes through it gets an unpredictable result in one, and often needs a fourth to deal with the consequences.
This article is educational material for clinicians. Intervals, volumes and session counts are deliberately not specified: they are judgements about an individual bed, and a number printed on a website would be a poor substitute for assessing the tissue in front of you.
Important information This article is general education, not medical advice. Tap to read the full medical, regulatory & legal notice.
This article is provided by Advanced Biomedical Concept for general informational and educational purposes only. It does not constitute medical, surgical, diagnostic, or other professional healthcare advice, and it is not a substitute for consultation with a suitably qualified healthcare professional. Reading it creates no doctor–patient or other professional relationship. Nothing here should be used to diagnose, treat, cure, or prevent any disease or condition, or to make decisions about medical care. Always seek the advice of a physician or other qualified provider with any questions about a medical condition or treatment, and never disregard or delay professional advice because of something you have read here.
Any reference to Advanced Biomedical Concept products (including ExaShape and ExaFat) is provided for general information only. These are medical devices intended to be used by appropriately trained healthcare professionals strictly in accordance with their applicable, current Instructions for Use (IFU). Regulatory status (including CE marking and classification under the EU Medical Device Regulation), market availability, and approved indications differ between countries and may change over time; a device referred to here may not be available or approved in your country. This content is not intended as, and must not be relied upon as, a statement or claim of safety, clinical performance, or efficacy beyond what is set out in the applicable IFU and current regulatory approvals. Product-specific information is directed at healthcare professionals and is not intended to promote, advertise, or offer any medical device to the general public where such promotion is restricted or prohibited by law.
Statements reflect information believed to be accurate at the date of publication and may be updated or corrected without notice. Any statements regarding the future are expectations or general views, not guarantees. Clinical outcomes depend on many individual factors, results vary from person to person, and no particular result is promised or implied. Where third-party studies, sources, or external links are referenced, they are provided for convenience and information only and do not imply endorsement, and Advanced Biomedical Concept is not responsible for their content.
To the fullest extent permitted by applicable law, Advanced Biomedical Concept and its officers, employees, contributors, and representatives (each acting in that capacity and on behalf of Advanced Biomedical Concept) accept no liability for any loss, injury, or damage of any kind arising directly or indirectly from use of, or reliance on, this content. Nothing in this notice excludes or limits any liability that cannot lawfully be excluded or limited.
Questions about this material can be directed to us via our contact page.
Last reviewed: September 25, 2026.